Tengion, Inc.
TNGNQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$402
Close$
Share Statistics
| Market cap | $402.00 |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.6 |
| Beta | 79.9 |
| Outstanding Shares | 25,171,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tengion, Inc.
25 employees
CEO: David I. Scheer Tengion, Inc. was a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. Its primary objective was the discovery, development, manufacturing, and commercializatio...